Johnson & Johnson

JNJ10 Dec 2024
Healthcare
$149.29
+0.00 (+0.24%)
Lowest Today
$148.48
Highest Today
$150.86
Today’s Open
$149.29
Prev. Close
$149.31
52 Week High
$167.51
52 Week Low
$139.79
To Invest in Johnson & Johnson

Johnson & Johnson

Healthcare
JNJ10 Dec 2024
+0.00 (+0.24%)
1M
3M
6M
1Y
5Y
Low
$148.48
Day’s Range
High
$150.86
148.48
52 Week Low
$139.79
52-Week Range
52 Week High
$167.51
139.79
1 Day
-
1 Week
-3.54%
1 month return
-3.98%
3 month return
-10.37%
6 month return
+1.44%
1 Year return
-3.26%
3 Years return
-9.17%
5 Years return
+6.26%
10 Years return
-
Institutional Holdings
Vanguard Group Inc
9.6
BlackRock Inc
8.23
State Street Corp
5.58
Vanguard Total Stock Mkt Idx Inv
3.16
Vanguard Institutional 500 Index Trust
2.65
Geode Capital Management, LLC
2.33
Morgan Stanley - Brokerage Accounts
1.88

Market Status

Fundamentals
Market Cap
359481.74 mln
PB Ratio
5.13
PE Ratio
24.68
Enterprise Value
375441.79 mln
Total Assets
167558 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Organisation
Johnson & Johnson
Employees
131900
Industry
Drug Manufacturers - General
CEO
Mr. Joaquin  Duato
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step